Eli Lilly: FDA Approves Verzenio In Adjuvant Treatment Of HR+ HER2- Early Breast Cancer
INDIANAPOLIS (dpa-AFX) - Eli Lilly and Company (LLY) said the FDA has approved its Verzenio, in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor-positive